journal article·2011Open access

Estimation of Particle Deposition in the Airways from Different Inhaler Formulations Using an In Silico Model

Hugh D.C. Smyth, Ted B. Martonen, Kristin K. Isaacs, Anthony J. Hickey

KONA Powder and Particle Journal· Volume 29· Issue 0

Abstract

The objective of these studies was to evaluate the use of an in silico model for predicting lung deposition of inhaled therapeutic aerosols. A range of input data derived from our own in vitro data and published clinical studies was utilized. The in silico model ran simulations for these propellant driven metered dose inhaler formulations across a range of conditions. Firstly, a range of pressurized metered dose inhaler formulations were evaluated in the in silico model and compared to the in vitro aerosol performance data. Limitations of using in vitro cascade impaction data were observed. Then, using in vivo data from healthy human subjects using metered dose inhalers, lung deposition profiles were compared with the in silico model predictions. Despite differences in oropharyngeal deposition the model predicted lung deposition accurately. We conclude that the in silico model can be applied to various conditions for particulate based inhalation aerosol systems.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Inhalation and Respiratory Drug Delivery · Microencapsulation and Drying Processes

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

College of Pharmacy, University of Texas at Austin

CyberMedicine, Inc.

United States Environmental Protection Agency

Eshelman School of Pharmacy, University of North Carolina at Chapel Hill

Funding

U.S. Environmental Protection Agency

References (25)

Show source-provided references
1. 1) Usmani, O. S., Biddiscombe, M. F., Nightingale, J. A., Underwood, S. R. and Barnes, P. J. (2003): Effects of bronchodilator particle size in asthmatic patients using monodisperse aerosols, J Appl Physiol, 95, pp. 2106–2112.10.1152/japplphysiol.00525.2003 ↗
2. 2) Smyth, H. D. C. and Leach, C. L. (2006): Alternative Propellant Aerosol Delivery Systems, Critical ReviewsTM in Therapeutic Drug Carrier Systems, 22(6), pp.493–534.10.1615/CritRevTherDrugCarrierSyst.v22.i6.10 ↗
3. 3) Smyth, H. D. C. (2005): Propellant-Driven Metered-Dose Inhalers For Pulmonary Drug Delivery, Expert Opinion on Drug Delivery, 2(1), pp.53–74.10.1517/17425247.2.1.53 ↗
4. 4) Smyth, H. D. C. (2003): The Influence Of Formulation Variables On The Performance Of Alternative Propellant-Driven Metered Dose Inhalers, Advanced Drug Delivery Reviews, 55(7), pp. 807–828.10.1016/S0169-409X(03)00079-6 ↗
5. 5) Smyth, H. D. C., Beck, V.P., Williams, D. and Hickey, A. J. (2004): The Influence Of Formulation And Spacer Device On The In Vitro Performance Of Solution Chlorofluorocarbon-Free Propellant-Driven Metered Dose Inhalers, AAPS PharmSciTech, 5(1), Article 7.10.1208/pt050107 ↗
6. 6) Smyth, H. D. C., Isaacs, K., Martonen, T. and Hickey, A. J. (2008): In Silico Predictions of Lung Deposition for Solution HFA 134a pMDIs with Spacers, Respiratory Drug Delivery 2008, Vol 3, pp 873–876.
7. 7) Martonen, T. B. (1993): Mathematical model for the selective deposition of inhaled pharmaceuticals, J. Pharm. Sci., 82, pp. 1191–1199.10.1002/jps.2600821202 ↗
8. 8) Martonen, T., Fleming, J., Schroeter, J., Conway, J. and Hwang, D. (2003): In silico modeling of asthma, Adv. Drug Deliv. Rev., Jul 18, 55(7), pp. 829–49.10.1016/S0169-409X(03)00080-2 ↗
9. 9) Martonen, T. B., Rosati, J. and Isaacs, K. K. (2004): Modeling particle deposition in human airways, In: Aerosols Handbook, Measurement, Dosimetry, and Health Effects, Ruzer, L. and Harley, N. editors. CRC Press.
10. 10) Heyder, J., Gebhardt, J., Rudolf, G., Schiller, C.F. and Stahlhofen, W. (1986): Deposition of particles in the human respiratory tract in the size range 0.005–15 μm, J. Aerosol Sci., 17, pp. 811–825.10.1016/0021-8502(86)90035-2 ↗
11. 11) Soong, T. T., Nicolaides, P., Yu, C. P. and Soong, S. C. (1979): A statistical description of the human tracheobronchial tree geometry, Respir Physiol., 37, pp. 161–172.10.1016/0034-5687(79)90068-9 ↗
12. 12) Schroeter, J. D., Fleming, J. S., Hwang, D. and Martonen, T. B. (2002): A computer model of lung morphology to analyze SPECT images, Comput. Med. Img. Graph., 26, pp. 237–246.10.1016/S0895-6111(02)00014-9 ↗
13. 13) Burton, R., Isaacs, K. K., Fleming, J. and Martonen, T. B. (2004): Computer reconstruction of a human lung boundary model from magnetic resonance images Respir Care 49(2), pp.180–185.10.4187/respcare.04490180 ↗
14. 14) Martonen, T. B., Smyth, H.D., Isaacs, K. K. and Burton, R. T. (2005): Issues in drug delivery: concepts and practice Respir Care Sep.50(9), pp.1228–52.10.4187/respcare.05501228 ↗
15. 15) Martonen, T. B. (1982): Analytical model of hygroscopic particle behavior in human airways, Bull. Math. Biol., 44, pp. 425–442.10.1016/S0092-8240(82)80021-9 ↗
16. 16) Martonen, T. B. and Guan, X. (2001): Effects of tumors on inhaled pharmacologic drugs. I. Flow patterns, Cell Biochem. Biophys., 35, p. 233.10.1385/CBB:35:3:233 ↗
17. 17) Martonen, T. B. and Guan, X. (2001): Effects of tumors on inhaled pharmacologic drugs. II. Particle motion, Cell Biochem. Biophys., 35, pp. 233–243.10.1385/CBB:35:3:233 ↗
18. 18) Martonen, T. B., Zhang, Z., Yue, G. and Musante, C. J. (2002): 3-D particle transport within the human upper respiratory tract, J. Aerosol Sci., 33, pp. 1095–1110.10.1016/S0021-8502(02)00060-5 ↗
19. 19) Isaacs, K. K., Martonen, T. B. and Schlesinger, R. (2006): Three-dimensional computational fluid dynamics simulations of particle deposition in the tracheobronchial tree J Aerosol Med.,19(3), pp. 344–52.10.1089/jam.2006.19.344 ↗
20. 20) Schlesinger, R. B., Gurman, J. L. and Lippmann, M. (1982): Particle deposition within bronchial airways: comparisons using constant and cyclic inspiratory flows Ann. Occup. Hyg. 26, pp.47–64.10.1016/B978-0-08-026838-5.50008-8 ↗
21. 21) Martonen, T. B, Schroeter, J. D. and Fleming, J. S. (2007): 3D in silico modeling of the human respiratory system for inhaled drug delivery and imaging analysis J Pharm Sci., 96(3), pp. 603–17.10.1002/jps.20707 ↗
22. 22) Smyth, H. D.C, Hickey, A. J. (2003): Multimodal Particle Size Distributions Emitted from HFA-134a Solution Pressurized Metered-Dose Inhalers, AAPS PharmSciTech, 4(3), article 38.10.1208/pt040338 ↗
23. 23) Leach, C. L., Davidson, P. J. and Boudreau, R. J. (1998): Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone Eur. Resp. J., 12(6), pp. 1346–1353.10.1183/09031936.98.12061346 ↗
24. 24) Leach, C. L., Davidson, P. J., Hasselquist, B. E. and Boudreau, R. J. (2002): Lung Deposition of Hydrofluoroalkane-134a Beclomethasone Is Greater Than That of Chlorofluorocarbon Fluticasone and Chlorofluorocarbon Beclomethasone : A Cross-over Study in Healthy Volunteers, Chest, 122(2), pp. 510–516.10.1378/chest.122.2.510 ↗
25. 25) Nave, R., Zech, K. and Bethke, T. D. (2005): Lower oropharyngeal deposition of inhaled ciclesonide via hydrofluoroalkane metered-dose inhaler compared with budesonide via chlorofluorocarbon metered-dose inhaler in healthy subjects, European Journal of Clinical Pharmacology, 61(3), pp. 203–208.10.1007/s00228-005-0910-0 ↗